Interpretation of Expert consensus on clinical diagnosis and treatment of sterile intraocular inflammation secondary to intraocular drug delivery (2025)
10.3760/cma.j.cn511434-20250617-00275
- VernacularTitle:《眼内注药治疗后非感染性眼内炎症诊疗专家共识（2025）》解读
- Author:
Heng MIAO
1
;
Xiaoxin LI
1
;
Mingwei ZHAO
1
Author Information
1. 北京大学人民医院眼科 眼病与视光医学北京市重点实验室,北京 100044
- Publication Type:Journal Article
- Keywords:
Intraocular drug delivery;
Sterile intraocular inflammation;
Evidence-based medicine;
Clinical practice guidelines;
Interpretation of expert consensus
- From:
Chinese Journal of Ocular Fundus Diseases
2025;41(9):675-678
- CountryChina
- Language:Chinese
-
Abstract:
With the recent domestic adoption of novel formulations such as high-dose anti-vascular endothelial growth factor agents and gene therapy drugs, sterile intraocular inflammation (SIOI) following intravitreal injection has gradually come into public awareness and garnered widespread attention. Concurrently, multiple ophthalmic medications with established clinical histories, including prophylactic antibiotics (e.g., vancomycin) and corticosteroids (e.g., triamcinolone acetonide), have also been reported to induce SIOI. To enhance Chinese ophthalmologists’ understanding of SIOI and standardize its diagnostic and therapeutic protocols, the Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association, adhering to evidence-based medicine principles and integrating international guidelines and consensus documents with China’s socioeconomic context, have spearheaded the development of the Expert consensus for the diagnosis and treatment of sterile intraocular inflammation after intraocular drug delivery (2025) through rigorous consensus-building processes. This consensus systematically presents diagnosis and treatment recommendations with Chinese characteristics, addressing seven key clinical issues such as the epidemiological features, clinical manifestations, identification of high-risk factors, perioperative management, and prognosis evaluation of SIOI. It focuses on constructing a hierarchical intervention system based on the severity of the disease. An in-depth understanding of the core content of this consensus can, on the one hand, help avoid diagnostic and therapeutic deviations caused by insufficient understanding, and on the other hand, assist in establishing a standardized SIOI management process, thereby effectively reducing the risk of visual impairment and optimizing the visual prognosis of patients. The introduction of this consensus marks the further improvement of the quality management system for intraocular injection therapy in our country and holds significant guiding importance for enhancing the diagnostic and therapeutic level of retinal diseases.
